April 28, 2026 – Dubai, United Arab Emirates
Built on Symbiotic Core and integrated into Midas’ open liquidity architecture, the partnership adds a capital-efficient RFQ settlement layer for tokenized assets T+0 atomic settlement with no idle capital and no pre-funded inventory.
Most tokenized assets remain functionally illiquid. Redemptions can take 60 to 180 days or more, leaving capital frozen between settlement events.
Tokenization solved access but deep, reliable liquidity at scale remains the open problem.
Symbiotic and Midas today announced the scope of the ‘instant liquidity’ product for tokenized assets, built on Symbiotic Core version two.
Symbiotic Instant Liquidity is an RFQ-based liquidity solution integrated as part of Midas’ open liquidity architecture.
It provides a highly capital-efficient approach to onchain RWA redemptions committed capital settles redemptions atomically without requiring pre-funded inventory or idle capital buffers, while maintaining its full function.
The solution targets most Midas assets, including Fasanara’s mGLOBAL, which was recently launched on the Midas platform.
The model is straightforward. An asset manager submits a redemption request, and Symbiotic-registered market makers and curators respond with bids through an onchain RFQ system.
The asset is priced, the best bid executes and settlement completes in a single transaction. Market makers do not need to pre-fund inventory and earn the spread on execution.
The same system also handles lending market liquidations, through Redstone Settle, which have historically been a key constraint in DeFi systems built on tokenized assets.
This is made possible by Symbiotic Core.
The upcoming version two upgrade introduces capital facilities, allowing capital in Symbiotic vaults to remain enforceable while being deployed between settlement events.
Instead of sitting idle, it can be allocated to whitelisted DeFi protocols like Morpho and Euler and automatically recalled when obligations trigger, enabling instant settlement without pre-funded liquidity.
Some other involved partners include Keyring and Term Finance.
Misha Putiatin, co-founder of Symbiotic, said,
“Liquidity is what turns an asset class into a market. The RWA space has been building toward trillions without it.
“Symbiotic Core changes that committed capital now functions as a liquidity sleeve, settling redemptions without sitting idle.
“This is what collateral markets infrastructure is built for.”
Midas recently closed a $50 million Series A to build institutional-grade tokenized financial products.
MGLOBAL is Fasanara’s flagship fund, tokenized on Midas and the first asset live on Symbiotic Instant Liquidity.
Integrated within Midas’ open liquidity architecture, this RFQ layer extends existing instant redemption capabilities with a fully onchain, capital-efficient settlement pathway open to qualified market makers.
Dennis Dinkelmeyer, co-founder and CEO of Midas, said,
“The biggest friction point for tokenized products has always been redemptions. You can put a fund onchain, but if exiting still takes several weeks, you haven’t really solved anything.
“Symbiotic Instant Liquidity, as part of Midas’ open liquidity architecture, changes that equation.
“On top of that, the capital backing redemptions is productive until the moment it’s needed, then settles atomically.”
Instant Liquidity is one product on Symbiotic’s collateral markets ecosystem. Cap Labs, operating in credit, and Nexus Mutual, operating in insurance, are already live.
Three different financial products, three different markets, one shared infrastructure.
Any issuer can integrate. Any market maker can participate.
About Symbiotic
Symbiotic powers collateral markets, where capital is committed to financial obligations and enforced by code.
Capital remains productive while committed, removing the tradeoff between being locked and earning. It backs products across credit, insurance, stablecoins and RWA.
Symbiotic powers more than 80 vaults, over 74,000 active stakers and 111 operators, with Chainlink, Nexus Mutual and Cap Labs live in production.
Backed by Paradigm, Pantera, Cyber.fund and Coinbase Ventures.
symbiotic.fi
About Midas
Midas is a platform for composable onchain investment products that enables strategy managers to tokenize their institutional strategies.
These ‘mTokens’ offer investors full transparency, instant redemptions and native composability across DeFi protocols such as Morpho and Pendle.
Founded in 2024 by Dennis Dinkelmeyer (formerly Goldman Sachs), Fabrice Grinda (FJ Labs) and Romain Bourgois (formerly Ondo Finance), Midas is backed by leading investors including RRE, Creandum, Framework Ventures, HV Capital, Ledger Cathay and Coinbase Ventures.
The company recently secured $50 million in Series A funding, building on a track record that includes over $1.7 billion in asset issuance and $37 million in yield paid out to date.
Contact
Mia Adriaens, marketing for Symbiotic
This post Symbiotic and Midas Build Instant Liquidity for Tokenized Assets may be modified as updates unfold.
Please note, this site provides content for entertainment purposes only and does not offer financial advice. Read more here
